# Official Journal C 228/2007

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 228 |
| | |
| English edition | Information and Notices | Volume 5028 September 2007 |

ISSN 1725-2423

Official Journal

of the European Union

C 228

English edition

Information and Notices

Volume 5028 September 2007

---

| Notice No | Contents | page |
| --- | --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES |
| | Commission |
| 2007/C 228/01 | Euro exchange rates | 1 |
| 2007/C 228/02 | Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 August 2007 to 31 August 2007(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council
  ) | 2 |
| 2007/C 228/03 | Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 August 2007 to 31 August 2007(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council
  or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council
  ) | 11 |
| | NOTICES FROM MEMBER STATES |
| 2007/C 228/04 | Imposition of a public service obligation in respect of scheduled air services within Italy (
  1
  ) | 13 |

Notice No

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

2007/C 228/01

Euro exchange rates

1

2007/C 228/02

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 August 2007 to 31 August 2007(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council
  )

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council

)

2

2007/C 228/03

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 August 2007 to 31 August 2007(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council
  or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council
  )

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council

or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council

)

11

NOTICES FROM MEMBER STATES

2007/C 228/04

Imposition of a public service obligation in respect of scheduled air services within Italy (
  1
  )

1

13

| | V   Announcements |
| --- | --- |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY |
| | Commission |
| 2007/C 228/05 | Prior notification of a concentration (Case COMP/M.4735 — OSRAM/Sunny World) (
  1
  ) | 16 |
| 2007/C 228/06 | Prior notification of a concentration (Case COMP/M.4824 — Kraft/Danone Biscuits) (
  1
  ) | 17 |
| | OTHER ACTS |
| | Commission |
| 2007/C 228/07 | Publication of an application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs | 18 |

V   Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY

Commission

2007/C 228/05

Prior notification of a concentration (Case COMP/M.4735 — OSRAM/Sunny World) (
  1
  )

1

16

2007/C 228/06

Prior notification of a concentration (Case COMP/M.4824 — Kraft/Danone Biscuits) (
  1
  )

1

17

OTHER ACTS

Commission

2007/C 228/07

Publication of an application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs

18

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

| 28.9.2007 | EN | Official Journal of the European Union | C 228/1 |
| --- | --- | --- | --- |

28.9.2007

EN

Official Journal of the European Union

C 228/1

---

Euro exchange rates (1)

27 September 2007

(2007/C 228/01)

1 euro=

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,4180 |
| JPY | Japanese yen | 163,29 |
| DKK | Danish krone | 7,4559 |
| GBP | Pound sterling | 0,69930 |
| SEK | Swedish krona | 9,2207 |
| CHF | Swiss franc | 1,6577 |
| ISK | Iceland króna | 87,26 |
| NOK | Norwegian krone | 7,7500 |
| BGN | Bulgarian lev | 1,9558 |
| CYP | Cyprus pound | 0,5842 |
| CZK | Czech koruna | 27,606 |
| EEK | Estonian kroon | 15,6466 |
| HUF | Hungarian forint | 250,14 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,7048 |
| MTL | Maltese lira | 0,4293 |
| PLN | Polish zloty | 3,7785 |
| RON | Romanian leu | 3,3751 |
| SKK | Slovak koruna | 33,881 |
| TRY | Turkish lira | 1,7238 |
| AUD | Australian dollar | 1,6079 |
| CAD | Canadian dollar | 1,4163 |
| HKD | Hong Kong dollar | 11,0011 |
| NZD | New Zealand dollar | 1,8862 |
| SGD | Singapore dollar | 2,1150 |
| KRW | South Korean won | 1 304,84 |
| ZAR | South African rand | 9,7370 |
| CNY | Chinese yuan renminbi | 10,6560 |
| HRK | Croatian kuna | 7,2848 |
| IDR | Indonesian rupiah | 12 960,52 |
| MYR | Malaysian ringgit | 4,8460 |
| PHP | Philippine peso | 63,916 |
| RUB | Russian rouble | 35,3460 |
| THB | Thai baht | 44,920 |

Currency

Exchange rate

USD

US dollar

1,4180

JPY

Japanese yen

163,29

DKK

Danish krone

7,4559

GBP

Pound sterling

0,69930

SEK

Swedish krona

9,2207

CHF

Swiss franc

1,6577

ISK

Iceland króna

87,26

NOK

Norwegian krone

7,7500

BGN

Bulgarian lev

1,9558

CYP

Cyprus pound

0,5842

CZK

Czech koruna

27,606

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

250,14

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,7048

MTL

Maltese lira

0,4293

PLN

Polish zloty

3,7785

RON

Romanian leu

3,3751

SKK

Slovak koruna

33,881

TRY

Turkish lira

1,7238

AUD

Australian dollar

1,6079

CAD

Canadian dollar

1,4163

HKD

Hong Kong dollar

11,0011

NZD

New Zealand dollar

1,8862

SGD

Singapore dollar

2,1150

KRW

South Korean won

1 304,84

ZAR

South African rand

9,7370

CNY

Chinese yuan renminbi

10,6560

HRK

Croatian kuna

7,2848

IDR

Indonesian rupiah

12 960,52

MYR

Malaysian ringgit

4,8460

PHP

Philippine peso

63,916

RUB

Russian rouble

35,3460

THB

Thai baht

44,920

---

(1)

Source: reference exchange rate published by the ECB.

---

| 28.9.2007 | EN | Official Journal of the European Union | C 228/2 |
| --- | --- | --- | --- |

28.9.2007

EN

Official Journal of the European Union

C 228/2

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 August 2007 to 31 August 2007

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council
   (1)
  )

(2007/C 228/02)

—   Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted

| Date of the decision | Name of the medicinal product | INN
  (International Non-Proprietary Name) | Holder of the marketing authorization | Number of the entry in the Community Register | Pharmaceutical form | ATC code
  (Anatomical Therapeutic Chemical Code) | Date of notification |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 3.8.2007 | INCRELEX | Mecasermin | Tercica Europe Limited |
| 2 Harbourmaster Place |
| International Financial Services Centre |
| Dublin 1 |
| Ireland |

Date of the decision

Name of the medicinal product

INN

(International Non-Proprietary Name)

Holder of the marketing authorization

Number of the entry in the Community Register

Pharmaceutical form

ATC code

(Anatomical Therapeutic Chemical Code)

Date of notification

3.8.2007

INCRELEX

Mecasermin

Tercica Europe Limited

2 Harbourmaster Place

International Financial Services Centre

Dublin 1

Ireland

EU/1/07/402/001

Solution for injection

H01AC03

7.8.2007

22.8.2007

Enviage

Aliskiren

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/07/406/001-020

Film-coated tablet

C09XA02

24.8.2007

22.8.2007

Riprazo

Aliskiren

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/07/409/001-020

Film-coated tablet

C09XA02

24.8.2007

22.8.2007

Sprimeo

Aliskiren

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/07/407/001-020

Film-coated tablet

C09XA02

24.8.2007

22.8.2007

Rasilez

Aliskiren

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/07/405/001-020

Film-coated tablet

C09XA02

24.8.2007

22.8.2007

Tekturna

Aliskiren

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/07/408/001-020

Film-coated tablet

C09XA02

24.8.2007

22.8.2007

Atriance

Nelarabine

| Glaxo Group Limited |
| --- |
| Berkeley Avenue |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Limited

Berkeley Avenue

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/07/403/001

Solution for infusion

L01BB07

24.8.2007

23.8.2007

Flebogammadif

Human normal immunoglobulin

| Instituto Grifols S.A. |
| --- |
| Can Guasch |
| 2 — Parets del Vallès |
| E-08150 Barcelona |

Instituto Grifols S.A.

Can Guasch

2 — Parets del Vallès

E-08150 Barcelona

EU/1/07/404/001-005

Solution for infusion

J06BA02

27.8.2007

28.8.2007

Abseamed

Epoetin alfa

| Medice Arzneimittel Pütter GmbH & Co KG |
| --- |
| Kuhloweg 37 |
| D-58638 Iserlohn |

Medice Arzneimittel Pütter GmbH & Co KG

Kuhloweg 37

D-58638 Iserlohn

EU/1/07/412/001-016

Solution for injection in a pre-filled syringe

B03XA01

31.8.2007

28.8.2007

Binocrit

Epoetin alfa

| Sandoz GmbH |
| --- |
| Biochemiestrasse 10 |
| A-6250 Kundl |

Sandoz GmbH

Biochemiestrasse 10

A-6250 Kundl

EU/1/07/410/001-016

Solution for injection in a pre-filled syringe

B03XA01

31.8.2007

28.8.2007

Epoetin alfa hexal

Epoetin alfa

| HEXAL Biotech Forschungs GmbH |
| --- |
| Industriestrasse 25 |
| D-83607 Holzkirchen |

HEXAL Biotech Forschungs GmbH

Industriestrasse 25

D-83607 Holzkirchen

EU/1/07/411/001-016

Solution for injection in a pre-filled syringe

B03XA01

3.9.2007

—   Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 1.8.2007 | Keppra | UCB S.A. |
| Allée de la Recherche, 60 |
| B-1070 Bruxelles |
| Researchdreef, 60 |
| B-1070 Brussel |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

1.8.2007

Keppra

UCB S.A.

Allée de la Recherche, 60

B-1070 Bruxelles

Researchdreef, 60

B-1070 Brussel

| UCB Pharma SA. |
| --- |
| Allée de la Recherche 60 |
| B-1070 Bruxelles |
| Researchdreef, 60 |
| B-1070 Brussel |

UCB Pharma SA.

Allée de la Recherche 60

B-1070 Bruxelles

Researchdreef, 60

B-1070 Brussel

EU/1/00/146/001-030

3.8.2007

3.8.2007

TachoSil

| Nycomed Austria GMBH |
| --- |
| St.-Peter-Straße 25 |
| A-4020 Linz |

Nycomed Austria GMBH

St.-Peter-Straße 25

A-4020 Linz

EU/1/04/277/001-004

7.8.2007

7.8.2007

BeneFIX

| Wyeth Europa Ltd |
| --- |
| Huntercombe Lane South Taplow |
| Maidenhead |
| Berkshire SL6 0PH |
| United Kingdom |

Wyeth Europa Ltd

Huntercombe Lane South Taplow

Maidenhead

Berkshire SL6 0PH

United Kingdom

EU/1/97/047/001-007

9.8.2007

10.8.2007

Norvir

| Abbott laboratories Ltd |
| --- |
| Queenborough |
| Kent ME11 5EL |
| United Kingdom |

Abbott laboratories Ltd

Queenborough

Kent ME11 5EL

United Kingdom

EU/1/96/016/001

EU/1/96/016/003-004

14.8.2007

10.8.2007

Fasturtec

| Sanofi-Aventis |
| --- |
| 174, avenue de France |
| F-75013 Paris |

Sanofi-Aventis

174, avenue de France

F-75013 Paris

EU/1/00/170/001-002

14.8.2007

10.8.2007

Ceprotin

| Baxter AG |
| --- |
| Industriestraße 67 |
| A-1220 Vienna |

Baxter AG

Industriestraße 67

A-1220 Vienna

EU/1/01/190/001-002

14.8.2007

10.8.2007

Cellcept

| Roche Registration Limited |
| --- |
| 6 Falcon Way |
| Shire Park |
| Welwyn Garden City AL7 1TW |
| United Kingdom |

Roche Registration Limited

6 Falcon Way

Shire Park

Welwyn Garden City AL7 1TW

United Kingdom

EU/1/96/005/001-006

14.8.2007

10.8.2007

Rebif

| Serono Europe Limited |
| --- |
| 56, Marsh Wall |
| London E14 9TP |
| United Kingdom |

Serono Europe Limited

56, Marsh Wall

London E14 9TP

United Kingdom

EU/1/98/063/001-007

14.8.2007

10.8.2007

Tritanrix HepB

| GlaxoSmithKline Biologicals S.A. |
| --- |
| rue de l'Institut, 89 |
| B-1330 Rixensart |

GlaxoSmithKline Biologicals S.A.

rue de l'Institut, 89

B-1330 Rixensart

EU/1/96/014/001-003

14.8.2007

10.8.2007

Cialis

| Lilly ICOS Limited |
| --- |
| St Bride's House |
| 10 Salisbury Square |
| London EC4Y 8EH |
| United Kingdom |

Lilly ICOS Limited

St Bride's House

10 Salisbury Square

London EC4Y 8EH

United Kingdom

EU/1/02/237/001-008

22.8.2007

20.8.2007

Actos

| Takeda Global Research and Development Centre (Europe) Ltd |
| --- |
| Arundel Great Court |
| 2 Arundel Street |
| London WC2R 3DA |
| United Kingdom |

Takeda Global Research and Development Centre (Europe) Ltd

Arundel Great Court

2 Arundel Street

London WC2R 3DA

United Kingdom

EU/1/00/150/001-024

22.8.2007

20.8.2007

Glustin

| Takeda Global Research and Development Centre (Europe) Ltd |
| --- |
| Arundel Great Court |
| 2 Arundel Street |
| London WC2R 3DA |
| United Kingdom |

Takeda Global Research and Development Centre (Europe) Ltd

Arundel Great Court

2 Arundel Street

London WC2R 3DA

United Kingdom

EU/1/00/151/001-022

22.8.2007

20.8.2007

Competact

| Takeda Global Research and Development Centre (Europe) Ltd |
| --- |
| Arundel Great Court |
| 2 Arundel Street |
| London WC2R 3DA |
| United Kingdom |

Takeda Global Research and Development Centre (Europe) Ltd

Arundel Great Court

2 Arundel Street

London WC2R 3DA

United Kingdom

EU/1/06/354/001-009

22.8.2007

21.8.2007

Forsteo

| Eli Lilly Nederland B.V. |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/03/247/001-002

23.8.2007

21.8.2007

Nexavar

| Bayer HealthCare AG |
| --- |
| D-51368 Leverkusen |

Bayer HealthCare AG

D-51368 Leverkusen

EU/1/06/342/001

23.8.2007

21.8.2007

Opatanol

| Alcon Laboratories (UK) Ltd |
| --- |
| Pentagon Park |
| Boundary Way |
| Hemel Hempstead |
| Herts HP2 7UD |
| United Kingdom |

Alcon Laboratories (UK) Ltd

Pentagon Park

Boundary Way

Hemel Hempstead

Herts HP2 7UD

United Kingdom

EU/1/02/217/001-002

23.8.2007

21.8.2007

NeuroBloc

| Solstice Neurosciences Ltd |
| --- |
| Fitzwilton House |
| Wilton Place |
| Dublin 2 |
| Ireland |

Solstice Neurosciences Ltd

Fitzwilton House

Wilton Place

Dublin 2

Ireland

EU/1/00/166/001-003

23.8.2007

21.8.2007

Avastin

| Roche Registration Limited |
| --- |
| 6 Falcon Way |
| Shire Park |
| Welwyn Garden City AL7 1TW |
| United Kingdom |

Roche Registration Limited

6 Falcon Way

Shire Park

Welwyn Garden City AL7 1TW

United Kingdom

EU/1/04/300/001-002

23.8.2007

21.8.2007

Kiovig

| Baxter AG |
| --- |
| Industriestraße 67 |
| A-1220 Vienna |

Baxter AG

Industriestraße 67

A-1220 Vienna

EU/1/05/329/001-005

23.8.2007

22.8.2007

Sprycel

| Bristol-Myers Squibb Pharma EEIG |
| --- |
| Uxbridge Business Park |
| Sanderson Road |
| Uxbridge UD8 1DH |
| United Kingdom |

Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park

Sanderson Road

Uxbridge UD8 1DH

United Kingdom

EU/1/06/363/001-009

24.8.2007

22.8.2007

Luminity

| Bristol-Myers Squibb Pharma Belgium Sprl |
| --- |
| Chaussée de la Hulpe, 185 |
| B-1170 Brussel |

Bristol-Myers Squibb Pharma Belgium Sprl

Chaussée de la Hulpe, 185

B-1170 Brussel

EU/1/06/361/001-002

24.8.2007

22.8.2007

Emtriva

| Gilead Sciences International Limited |
| --- |
| Cambridge CB21 6GT |
| United Kingdom |

Gilead Sciences International Limited

Cambridge CB21 6GT

United Kingdom

EU/1/03/261/001-003

24.8.2007

22.8.2007

Baraclude

| Bristol-Myers Squibb Pharma EEIG |
| --- |
| Uxbridge Business Park |
| Sanderson Road |
| Uxbridge UD8 1DH |
| United Kingdom |

Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park

Sanderson Road

Uxbridge UD8 1DH

United Kingdom

EU/1/06/343/001-005

24.8.2007

23.8.2007

Inovelon

| Eisai Limited, 3 |
| --- |
| Shortlands |
| London W6 8EE |
| United Kingdom |

Eisai Limited, 3

Shortlands

London W6 8EE

United Kingdom

EU/1/06/378/001-016

28.8.2007

23.8.2007

Stocrin

| Merck Sharp & Dohme Ltd |
| --- |
| Hertford Road |
| Hoddesdon |
| Hertfordshire EN11 9BU |
| United Kingdom |

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/99/111/001-011

28.8.2007

23.8.2007

Sustiva

| Bristol-Myers Squibb Pharma EEIG |
| --- |
| Uxbridge Business Park |
| Sanderson Road |
| Uxbridge UD8 1DH |
| United Kingdom |

Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park

Sanderson Road

Uxbridge UD8 1DH

United Kingdom

EU/1/99/110/001-009

28.8.2007

23.8.2007

Orfadin

| Swedish Orphan International AB |
| --- |
| Drottninggatan 98 |
| S-111 60 Stockholm |

Swedish Orphan International AB

Drottninggatan 98

S-111 60 Stockholm

EU/1/04/303/001-003

27.8.2007

27.8.2007

Kivexa

| Glaxo Group Ltd |
| --- |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/04/298/001-002

29.8.2007

27.8.2007

Ziagen

| Glaxo Group Ltd |
| --- |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/99/112/001-002

29.8.2007

27.8.2007

Rapamune

| Wyeth Europa Limited |
| --- |
| Huntercombe Lane South Taplow |
| Maidenhead |
| Berkshire SL6 0PH |
| United Kingdom |

Wyeth Europa Limited

Huntercombe Lane South Taplow

Maidenhead

Berkshire SL6 0PH

United Kingdom

EU/1/01/171/001

EU/1/01/171/007-012

29.8.2007

27.8.2007

Prezista

| Janssen-Cilag International NV |
| --- |
| Turnhoutseweg, 30 |
| B-2340 Beerse |

Janssen-Cilag International NV

Turnhoutseweg, 30

B-2340 Beerse

EU/1/06/380/001

29.8.2007

27.8.2007

NovoMix

| Novo Nordisk A/S |
| --- |
| Novo Allé |
| DK-2880 Bagsværd |

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

EU/1/00/142/004-005

EU/1/00/142/009-022

29.8.2007

27.8.2007

Invanz

| Merck Sharp & Dohme Ltd |
| --- |
| Hertford Road |
| Hoddesdon |
| Hertfordshire EN11 9BU |
| United Kingdom |

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/02/216/001-002

29.8.2007

27.8.2007

Tandemact

| Takeda Global Research and Development Centre (Europe) Ltd |
| --- |
| Arundel Great Court |
| 2 Arundel Street |
| London WC2R 3DA |
| United Kingdom |

Takeda Global Research and Development Centre (Europe) Ltd

Arundel Great Court

2 Arundel Street

London WC2R 3DA

United Kingdom

EU/1/06/366/001-004

29.8.2007

27.8.2007

Ebixa

| H. Lundbeck A/S |
| --- |
| Ottiliavej 9 |
| DK-2500 Valby |

H. Lundbeck A/S

Ottiliavej 9

DK-2500 Valby

EU/1/02/219/001-015

29.8.2007

29.8.2007

Enbrel

| Wyeth Europa Limited |
| --- |
| Huntercombe Lane South Taplow |
| Maidenhead |
| Berkshire SL6 0PH |
| United Kingdom |

Wyeth Europa Limited

Huntercombe Lane South Taplow

Maidenhead

Berkshire SL6 0PH

United Kingdom

EU/1/99/126/001-018

31.8.2007

28.8.2007

Cymbalta

| Eli Lilly Nederland B.V. |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/04/296/001-009

31.8.2007

28.8.2007

Xeristar

| Boehringer Ingelheim International GmbH |
| --- |
| Binger Straße 173 |
| D-55216 Ingelheim am Rhein |

Boehringer Ingelheim International GmbH

Binger Straße 173

D-55216 Ingelheim am Rhein

EU/1/04/297/001-008

31.8.2007

28.8.2007

YENTREVE

| Eli Lilly Nederland B.V. |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/04/280/001-008

31.8.2007

28.8.2007

Ariclaim

| Eli Lilly Nederland B.V. |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/04/283/001-007

31.8.2007

29.8.2007

Stalevo

| Orion Corporation |
| --- |
| Orionintie 1 |
| FIN-02200 Espoo |

Orion Corporation

Orionintie 1

FIN-02200 Espoo

EU/1/03/260/001-018

31.8.2007

29.8.2007

Exubera

| Pfizer Ltd |
| --- |
| Ramsgate Road |
| Sandwich |
| Kent CT 13 9NJ |
| United Kingdom |

Pfizer Ltd

Ramsgate Road

Sandwich

Kent CT 13 9NJ

United Kingdom

EU/1/05/327/001-018

31.8.2007

29.8.2007

Vistide

| Pfizer Enterprises SARL |
| --- |
| 51, Avenue Kennedy |
| Rond Point du Kirchberg |
| L-1855 Luxembourg |

Pfizer Enterprises SARL

51, Avenue Kennedy

Rond Point du Kirchberg

L-1855 Luxembourg

EU/1/97/037/001

31.8.2007

29.8.2007

Evoltra

| Bioenvision Limited |
| --- |
| Bassett House |
| 5 Southwell Park Road |
| Camberley |
| Surrey GU15 3PU |
| United Kingdom |

Bioenvision Limited

Bassett House

5 Southwell Park Road

Camberley

Surrey GU15 3PU

United Kingdom

EU/1/06/334/001-004

31.8.2007

29.8.2007

Xelevia

| Merck Sharp & Dohme Ltd |
| --- |
| Hertford Road |
| Hoddesdon |
| Hertfordshire EN11 9BU |
| United Kingdom |

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/07/382/001-018

31.8.2007

29.8.2007

Januvia

| Merck Sharp & Dohme Ltd |
| --- |
| Hertford Road |
| Hoddesdon |
| Hertfordshire EN11 9BU |
| United Kingdom |

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/07/383/001-018

31.8.2007

29.8.2007

Quixidar

| Glaxo Group Ltd |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/02/207/001-004

31.8.2007

29.8.2007

Quixidar

| Glaxo Group Ltd |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/02/207/001-004

31.8.2007

29.8.2007

Arixtra

| Glaxo Group Ltd |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/02/206/001-004

31.8.2007

29.8.2007

Arixtra

| Glaxo Group Ltd |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/02/206/001-004

31.8.2007

30.8.2007

Fuzeon

| Roche Registration Limited |
| --- |
| 6 Falcon Way |
| Shire Park |
| Welwyn Garden City AL7 1TW |
| United Kingdom |

Roche Registration Limited

6 Falcon Way

Shire Park

Welwyn Garden City AL7 1TW

United Kingdom

EU/1/03/252/001-003

5.9.2007

30.8.2007

BYETTA

| Eli Lilly Nederland B.V. |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/06/362/001-004

5.9.2007

30.8.2007

Agenerase

| Glaxo Group Limited |
| --- |
| Berkeley Avenue |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Limited

Berkeley Avenue

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/00/148/001-004

5.9.2007

30.8.2007

Aranesp

| Amgen Europe B.V. |
| --- |
| Minervum 7061 |
| 4817 ZK Breda |
| Nederland |

Amgen Europe B.V.

Minervum 7061

4817 ZK Breda

Nederland

EU/1/01/185/001-073

5.9.2007

30.8.2007

NovoRapid

| Novo Nordisk A/S |
| --- |
| Novo Allé |
| DK-2880 Bagsværd |

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

EU/1/99/119/001

EU/1/99/119/003

EU/1/99/119/005-014

5.9.2007

30.8.2007

Nespo

| Dompé Biotec S.p.A. |
| --- |
| Via San Martino 12 |
| I-20122 Milano |

Dompé Biotec S.p.A.

Via San Martino 12

I-20122 Milano

EU/1/01/184/001-073

5.9.2007

30.8.2007

Zyprexa

| Eli Lilly Nederland B.V. |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/96/022/002

EU/1/96/022/004

EU/1/96/022/006

EU/1/96/022/008-012

EU/1/96/022/014

EU/1/96/022/016-017

EU/1/96/022/019-034

5.9.2007

30.8.2007

Zyprexa Velotab

| Eli Lilly Nederland B.V. |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/99/125/001-016

5.9.2007

30.8.2007

InductOs

| Wyeth Europa Ltd |
| --- |
| Huntercombe Lane South Taplow |
| Maidenhead |
| Berkshire SL6 0PH |
| United Kingdom |

Wyeth Europa Ltd

Huntercombe Lane South Taplow

Maidenhead

Berkshire SL6 0PH

United Kingdom

EU/1/02/226/001

5.9.2007

30.8.2007

Aldara

| Laboratoires 3M Santé |
| --- |
| Boulevard de l'Oise |
| F-95029 Cergy Pontoise Cedex |

Laboratoires 3M Santé

Boulevard de l'Oise

F-95029 Cergy Pontoise Cedex

EU/1/98/080/001

5.9.2007

| Meda AB |
| --- |
| Pipers väg 2A |
| S-170 73 Solna |

Meda AB

Pipers väg 2A

S-170 73 Solna

5.9.2007

31.8.2007

Karvea

| Bristol-Myers Squibb Pharma EEIG |
| --- |
| Uxbridge Business Park |
| Sanderson Road |
| Uxbridge UD8 1DH |
| United Kingdom |

Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park

Sanderson Road

Uxbridge UD8 1DH

United Kingdom

EU/1/97/049/001-039

6.9.2007

31.8.2007

Aprovel

| Sanofi Pharma Bristol-Myers Squibb SNC |
| --- |
| 174 avenue de France |
| F-75013 Paris |

Sanofi Pharma Bristol-Myers Squibb SNC

174 avenue de France

F-75013 Paris

EU/1/97/046/001-039

5.9.2007

31.8.2007

CUBICIN

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/05/328/001-002

5.9.2007

31.8.2007

Glustin

| Takeda Global Research and Development Centre (Europe) Ltd |
| --- |
| Arundel Great Court |
| 2 Arundel Street |
| London WC2R 3DA |
| United Kingdom |

Takeda Global Research and Development Centre (Europe) Ltd

Arundel Great Court

2 Arundel Street

London WC2R 3DA

United Kingdom

EU/1/00/151/001-024

5.9.2007

31.8.2007

Mimpara

| Amgen Europe B.V. |
| --- |
| Minervum 7061 |
| 4817 ZK Breda |
| Nederland |

Amgen Europe B.V.

Minervum 7061

4817 ZK Breda

Nederland

EU/1/04/292/001-012

6.9.2007

31.8.2007

Parareg

| Dompé Biotec S.p.A. |
| --- |
| Via San Martino 12 |
| I-20122 Milano |

Dompé Biotec S.p.A.

Via San Martino 12

I-20122 Milano

EU/1/04/293/001-012

6.9.2007

31.8.2007

Epivir

| Glaxo Group Ltd |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/96/015/001-005

6.9.2007

31.8.2007

Zimulti

| Sanofi-Aventis |
| --- |
| 174, avenue de France |
| F-75013 Paris |

Sanofi-Aventis

174, avenue de France

F-75013 Paris

EU/1/06/345/001-011

6.9.2007

31.8.2007

ACOMPLIA

| Sanofi-Aventis |
| --- |
| 174, avenue de France |
| F-75013 Paris |

Sanofi-Aventis

174, avenue de France

F-75013 Paris

EU/1/06/344/001-011

6.9.2007

31.8.2007

Prevenar

| Wyeth-Lederle Vaccines S.A. |
| --- |
| Rue du Bosquet |
| B-15-1348 Louvain-La-Neuve |

Wyeth-Lederle Vaccines S.A.

Rue du Bosquet

B-15-1348 Louvain-La-Neuve

EU/1/00/167/001-007

6.9.2007

—   Suspension of a marketing authorization (Article 20 of Regulation (EC) No 726/2004)

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 6.8.2007 | Viracept | Roche Registration Limited |
| 6 Falcon Way |
| Shire Park |
| Welwyn Garden City AL7 1TW |
| United Kingdom |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

6.8.2007

Viracept

Roche Registration Limited

6 Falcon Way

Shire Park

Welwyn Garden City AL7 1TW

United Kingdom

EU/1/97/054/001

EU/1/97/054/003-005

8.8.2007

—   Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 2.8.2007 | Dexdomitor | Orion Corporation |
| Orionintie 1 |
| FIN-02200 Espoo |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

2.8.2007

Dexdomitor

Orion Corporation

Orionintie 1

FIN-02200 Espoo

EU/2/02/033/001

6.8.2007

13.8.2007

Advocate

| Bayer HealthCare AG |
| --- |
| D-51368 Leverkusen |

Bayer HealthCare AG

D-51368 Leverkusen

EU/2/03/039/001-030

15.8.2007

23.8.2007

PRAC-TIC

| Novartis Sanidad Animal S.L. |
| --- |
| Calle de la Marina, 206 |
| E-08013 Barcelona |

Novartis Sanidad Animal S.L.

Calle de la Marina, 206

E-08013 Barcelona

EU/2/06/066/001-012

27.8.2007

27.8.2007

Yarvitan

| Janssen Animal Health B.V.B.A. |
| --- |
| Turnhoutseweg, 30 |
| B-2340 Beerse |

Janssen Animal Health B.V.B.A.

Turnhoutseweg, 30

B-2340 Beerse

EU/2/06/063/001-003

29.8.2007

| Janssen Pharmaceutica N.V. |
| --- |
| Turnhoutseweg, 30 |
| B-2340 Beerse |

Janssen Pharmaceutica N.V.

Turnhoutseweg, 30

B-2340 Beerse

29.8.2007

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| The European Medicines Agency |
| --- |
| 7, Westferry Circus |
| Canary Wharf |
| London E14 4HB |
| United Kingdom |

The European Medicines Agency

7, Westferry Circus

Canary Wharf

London E14 4HB

United Kingdom

---

(1)  OJ L 136, 30.4.2004, p. 1.

---

| 28.9.2007 | EN | Official Journal of the European Union | C 228/11 |
| --- | --- | --- | --- |

28.9.2007

EN

Official Journal of the European Union

C 228/11

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 August 2007 to 31 August 2007

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council
   (1)
  or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council
   (2)
  )

(2007/C 228/03)

—   Issuing, maintenance or modification of a national marketing authorisation

| Date of the decision | Name(s) of the medicinal product | Holder(s) of the marketing authorization | Member State concerned | Date of notification |
| --- | --- | --- | --- | --- |
| 3.8.2007 | INCRELEX | Tercica Europe Limited |
| 2 Harbourmaster Place |
| International Financial Services Centre |
| Dublin 1 |
| Ireland |

Date of the decision

Name(s) of the medicinal product

Holder(s) of the marketing authorization

Member State concerned

Date of notification

3.8.2007

INCRELEX

Tercica Europe Limited

2 Harbourmaster Place

International Financial Services Centre

Dublin 1

Ireland

This Decision is addressed to the Member States

6.8.2007

22.8.2007

Cefuroximaxetil

See Annex

See Annex

23.8.2007

28.8.2007

Abseamed

| Medice Arzneimittel Pütter GmbH & Co KG |
| --- |
| Kuhloweg 37 |
| D-58638 Iserlohn |

Medice Arzneimittel Pütter GmbH & Co KG

Kuhloweg 37

D-58638 Iserlohn

This Decision is addressed to the Member States

31.8.2007

28.8.2007

Binocrit

| Sandoz GmbH |
| --- |
| Biochemiestraße 10 |
| A-6250 Kundl |

Sandoz GmbH

Biochemiestraße 10

A-6250 Kundl

This Decision is addressed to the Member States

31.8.2007

28.8.2007

Epoetin alfa hexal

| HEXAL Biotech Forschungs GmbH |
| --- |
| Industriestraße 25 |
| D-83607 Holzkirchen |

HEXAL Biotech Forschungs GmbH

Industriestraße 25

D-83607 Holzkirchen

This Decision is addressed to the Member States

3.9.2007

---

(1)  OJ L 311, 28.11.2001, p. 67.

(2)  OJ L 311, 28.11.2001, p. 1.

---

ANNEX

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDER/APPLICANTS IN THE MEMBER STATES

| Member State | Marketing Authorisation Holder | Applicant | Invented name | Strength | Pharmaceutical Form | Route of administration |
| --- | --- | --- | --- | --- | --- | --- |
| The Netherlands | Sandoz B.V. |
| Veluwezoom 22 |
| 1327 Almere |
| Nederland |

Member State

Marketing Authorisation Holder

Applicant

Invented name

Strength

Pharmaceutical Form

Route of administration

The Netherlands

Sandoz B.V.

Veluwezoom 22

1327 Almere

Nederland

Cefuroximaxetil 125, omhulde tabletten 125 mg

125 mg

Coated tablets

Oral use

Cefuroximaxetil 250, omhulde tabletten 250 mg

250 mg

Cefuroximaxetil 500, omhulde tabletten 500 mg

500 mg

Estonia

| 1A Pharma GmbH |
| --- |
| Keltenring 1 + 3 |
| D-82041 Oberhaching |

1A Pharma GmbH

Keltenring 1 + 3

D-82041 Oberhaching

Cefuroxim 1A Pharma 125 mg

125 mg

Coated tablets

Oral use

Cefuroxim 1A Pharma 250 mg

250 mg

Cefuroxim 1A Pharma 500 mg

500 mg

Greece

| Sandoz GmbH |
| --- |
| Biochemiestraße 10 |
| A-6250 Kundl |

Sandoz GmbH

Biochemiestraße 10

A-6250 Kundl

Cefuroxime axetil Sandoz 250 mg

250 mg

Coated tablets

Oral use

Cefuroxime axetil Sandoz 500 mg

500 mg

Portugal

| Sandoz Farmacêutica Lda. |
| --- |
| Alameda da Quinta da Beloura |
| Edifício 1-Esc. 15 |
| P-2710-693 Sintra |

Sandoz Farmacêutica Lda.

Alameda da Quinta da Beloura

Edifício 1-Esc. 15

P-2710-693 Sintra

Cefuroxima Sandoz 250 mg comprimidos

250 mg

Coated tablets

Oral use

Cefuroxima Sandoz 500 mg comprimidos

500 mg

Spain

| Sandoz Farmacéutica, S.A. |
| --- |
| Gran Vía de les Corts Catalanes, 764 |
| E-08013 Barcelona |

Sandoz Farmacéutica, S.A.

Gran Vía de les Corts Catalanes, 764

E-08013 Barcelona

Cefuroxima Sandoz 125 mg comprimidos recubiertos con película EFG

125 mg

Coated tablets

Oral use

Cefuroxima Sandoz 250 mg comprimidos recubiertos con película EFG

250 mg

Cefuroxima Sandoz 500 mg comprimidos recubiertos con película EF

500 mg

---

NOTICES FROM MEMBER STATES

| 28.9.2007 | EN | Official Journal of the European Union | C 228/13 |
| --- | --- | --- | --- |

28.9.2007

EN

Official Journal of the European Union

C 228/13

---

Imposition of a public service obligation in respect of scheduled air services within Italy

(Text with EEA relevance)

(2007/C 228/04)

Pursuant to Article 4(1)(a) of Council Regulation (EEC) No 2408/92 of 23 July 1992 on access for Community air carriers to intra-Community air routes (1), the Italian Government, in accordance with the decisions taken at the interdepartmental conference chaired by the Region of Piedmont, has decided to impose public service obligations in respect of scheduled air services on the following route:

1.   Routes concerned

Cuneo Levaldigi-Rome Fiumicino and vice versa.

| 1.1. | Under Article 9 of Council Regulation (EEC) No 95/93 of 18 January 1993 on common rules for the allocation of slots at Community airports (2), as amended by Regulation (EC) No 793/2004 of the European Parliament and of the Council (3), the competent authorities may reserve certain slots for the operation of services under the terms specified in this notice. |
| --- | --- |

1.1.

Under Article 9 of Council Regulation (EEC) No 95/93 of 18 January 1993 on common rules for the allocation of slots at Community airports (2), as amended by Regulation (EC) No 793/2004 of the European Parliament and of the Council (3), the competent authorities may reserve certain slots for the operation of services under the terms specified in this notice.

| 1.2. | ENAC will verify whether the accepting carriers possess the requisite structure and meet the minimum requirements for access to the service in order to meet the objectives pursued by the imposition of the public service obligation. |
| --- | --- |

1.2.

ENAC will verify whether the accepting carriers possess the requisite structure and meet the minimum requirements for access to the service in order to meet the objectives pursued by the imposition of the public service obligation.

2.   Details of the public service obligation

2.1.   Minimum frequencies

| (a) | Cuneo Levaldigi-Rome Fiumicino and vice versa.
  The minimum frequency on the above route is as follows:






  — | at least one flight per day in each direction from Mondays to Fridays, throughout the year, using an aircraft with a seating capacity of at least 44, |
| --- | --- | --- |

(a)

Cuneo Levaldigi-Rome Fiumicino and vice versa.

The minimum frequency on the above route is as follows:

—

at least one flight per day in each direction from Mondays to Fridays, throughout the year, using an aircraft with a seating capacity of at least 44,

| — | at least one flight departing on a Saturday morning and one flight returning on a Sunday evening, throughout the year, using an aircraft with a seating capacity of at least 44. |
| --- | --- |

—

at least one flight departing on a Saturday morning and one flight returning on a Sunday evening, throughout the year, using an aircraft with a seating capacity of at least 44.

The whole capacity of each aircraft must be made available for sale under the public service obligation terms.

2.2.   Timetables

For the Cuneo Levaldigi-Rome Fiumicino route from Mondays to Saturdays the timetable must provide for at least one flight departing during the slot 6.45-7.45.

For the Rome Fiumicino-Cuneo Levaldigi route from Mondays to Fridays the timetable must provide for at least one flight departing during the slot 19.00-20.30.

For the Rome Fiumicino-Cuneo Levaldigi route on Sundays the timetable must provide for at least one flight departing during the slot 19.00-20.30.

2.3.   Aircraft used and capacity offered

The service from Cuneo Levaldigi to Rome Fiumicino and vice versa must be operated with a pressurised twin-turboprop or twin-jet aircraft having a seating capacity of at least 44.

If the market so requires, extra capacity must be provided through supplementary flights, which will not give rise to extra compensation or result in the application of fares different from those specified at 2.4 below.

The carrier which accepts the public service obligation must, subject to safety considerations which may justify denied boarding, make every effort to facilitate the carriage, on the aircraft used, of passengers with disabilities and passengers with reduced mobility.

2.4.   Fares

| (a) | The maximum fares to be charged on each route are as follows:
  Cuneo Levaldigi-Rome Fiumicino: EUR 90
  Rome Fiumicino-Cuneo Levaldigi: EUR 90
  The above fares exclude VAT and are net of airport taxes and charges; no form of surcharge may be levied.
  At least one form of ticket distribution and sale must be provided which is entirely free of charge and places no additional economic burden on passengers.
  All passengers who travel on the routes subject to this public service obligation will be entitled to the above fares. |
| --- | --- |

(a)

The maximum fares to be charged on each route are as follows:

Cuneo Levaldigi-Rome Fiumicino: EUR 90

Rome Fiumicino-Cuneo Levaldigi: EUR 90

The above fares exclude VAT and are net of airport taxes and charges; no form of surcharge may be levied.

At least one form of ticket distribution and sale must be provided which is entirely free of charge and places no additional economic burden on passengers.

All passengers who travel on the routes subject to this public service obligation will be entitled to the above fares.

| (b) | Every year the competent authorities will adjust the maximum fares in line with the rate of inflation of the previous year calculated on the basis of the ISTAT/FOI general consumer price index. Adjustments will be notified to all carriers operating the routes in question and to the European Commission for publication in the Official Journal of the European Union. |
| --- | --- |

(b)

Every year the competent authorities will adjust the maximum fares in line with the rate of inflation of the previous year calculated on the basis of the ISTAT/FOI general consumer price index. Adjustments will be notified to all carriers operating the routes in question and to the European Commission for publication in the Official Journal of the European Union.

| (c) | To mitigate the consequences of unusual variations in the price of fuel, every six months the amount will be calculated (Sp), whether positive or negative, to be added to or subtracted from the fare for the route:








  where | : | Sp | = | fare adjustment for the route (to the nearest unit) |
| --- | --- | --- | --- | --- | --- |
| K | = | average Euro/dollar exchange rate over the six-month period |
| B | = | average price per barrel of oil (Brent Dated) over the six-month period |
| T | = | fare for the route in question |

(c)

To mitigate the consequences of unusual variations in the price of fuel, every six months the amount will be calculated (Sp), whether positive or negative, to be added to or subtracted from the fare for the route:

where

:

Sp

=

fare adjustment for the route (to the nearest unit)

K

=

average Euro/dollar exchange rate over the six-month period

B

=

average price per barrel of oil (Brent Dated) over the six-month period

T

=

fare for the route in question

Six-monthly fare adjustments will be made, where appropriate, by the Minister for Transport in agreement with the President of the Region of Piedmont, on the basis of an examination carried out by a joint technical committee composed of one representative appointed by ENAC and one representative appointed by the Region of Piedmont. In the event of an increase, the joint technical committee will initiate the procedure for deciding on an adjustment upon receiving notice from the carriers operating the routes concerned. In the event of a decrease, the procedure will be initiated automatically. During the abovementioned examination procedure, the carriers operating the route concerned must be given an opportunity to comment. Any adjustment to fares will take effect as from the six-month period following that in which it is decided.

Adjustments will be notified to all carriers operating the routes and to the European Commission for publication in the Official Journal of the European Union.

2.5.   Continuity of service

For the purpose of guaranteeing the correct performance and continuity of the service, the carriers which accept the public service obligation must:

| — | guarantee the service for at least 12 consecutive months, and must not suspend it without at least six months' notice, |
| --- | --- |

—

guarantee the service for at least 12 consecutive months, and must not suspend it without at least six months' notice,

| — | ensure that their conduct vis-à-vis users conforms to the principles set out in the Charter of Passengers' Rights, so as to comply with the relevant national, Community and international regulations, |
| --- | --- |

—

ensure that their conduct vis-à-vis users conforms to the principles set out in the Charter of Passengers' Rights, so as to comply with the relevant national, Community and international regulations,

| — | provide a performance security for the purpose of guaranteeing the correct performance and continuation of the service. This must take the form of an insurance bond or bank security of EUR 500 000 to ENAC (the Italian National Civil Aviation Authority), which may use it to ensure the continuation of the public service obligation arrangements, |
| --- | --- |

—

provide a performance security for the purpose of guaranteeing the correct performance and continuation of the service. This must take the form of an insurance bond or bank security of EUR 500 000 to ENAC (the Italian National Civil Aviation Authority), which may use it to ensure the continuation of the public service obligation arrangements,

| — | carry out at least 98 % of the flights scheduled in any year, with the number of cancellations for reasons directly attributable to the carrier, excluding cases of force majeure, limited to a maximum of 2 %, |
| --- | --- |

—

carry out at least 98 % of the flights scheduled in any year, with the number of cancellations for reasons directly attributable to the carrier, excluding cases of force majeure, limited to a maximum of 2 %,

| — | pay the regulatory body a penalty of EUR 3 000 for every flight cancelled in excess of the 2 % limit. The sums paid under this provision will be reallocated to territorial continuity on the route Cuneo Levaldigi-Rome Fiumicino and vice versa. |
| --- | --- |

—

pay the regulatory body a penalty of EUR 3 000 for every flight cancelled in excess of the 2 % limit. The sums paid under this provision will be reallocated to territorial continuity on the route Cuneo Levaldigi-Rome Fiumicino and vice versa.

The penalties under this section may be combined with those under Legislative Decree No 69 of 27 January 2006 laying down provisions governing penalties for contravening Regulation (EC) No 261/2004 establishing common rules on compensation and assistance to passengers in the event of denied boarding and of cancellation or long delay of flights.

This public service obligation replaces the obligation published in
  Official Journal of the European Union C 213 of 5 September 2006.

---

(1)  OJ L 240, 24.8.1992, p. 8.

(2)  OJ L 14, 22.1.1993, p. 1.

(3)  OJ L 138, 30.4.2004, p. 50.

---

V Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY

Commission

| 28.9.2007 | EN | Official Journal of the European Union | C 228/16 |
| --- | --- | --- | --- |

28.9.2007

EN

Official Journal of the European Union

C 228/16

---

Prior notification of a concentration

(Case COMP/M.4735 — OSRAM/Sunny World)

(Text with EEA relevance)

(2007/C 228/05)

| 1. | On 20 September 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking OSRAM GmbH (‘OSRAM’, Germany) controlled by Siemens AG (Germany) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Sunny World Ltd (‘Sunny World’, Hong Kong) by way of purchase of shares. |
| --- | --- |

1.

On 20 September 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking OSRAM GmbH (‘OSRAM’, Germany) controlled by Siemens AG (Germany) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Sunny World Ltd (‘Sunny World’, Hong Kong) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for OSRAM: development, production and sale of a wide range of lighting products such as lamps, luminaries and ballasts, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for OSRAM: development, production and sale of a wide range of lighting products such as lamps, luminaries and ballasts,

| — | for Sunny World: development and production of integrated Compact Fluorescent Lamps (CFLi) and Incandescent General Purpose Lamps (GLS). |
| --- | --- |

—

for Sunny World: development and production of integrated Compact Fluorescent Lamps (CFLi) and Incandescent General Purpose Lamps (GLS).

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4735 — OSRAM/Sunny World, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Bruxelles/Brussel |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4735 — OSRAM/Sunny World, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Bruxelles/Brussel

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 28.9.2007 | EN | Official Journal of the European Union | C 228/17 |
| --- | --- | --- | --- |

28.9.2007

EN

Official Journal of the European Union

C 228/17

---

Prior notification of a concentration

(Case COMP/M.4824 — Kraft/Danone Biscuits)

(Text with EEA relevance)

(2007/C 228/06)

| 1. | On 19 September 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Kraft Foods Global Inc., controlled by Kraft Foods Inc. (‘Kraft’, USA) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the worldwide biscuits, snacks and cereals business of Danone (‘Danone Biscuits’, France) by way of purchase of shares. |
| --- | --- |

1.

On 19 September 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Kraft Foods Global Inc., controlled by Kraft Foods Inc. (‘Kraft’, USA) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the worldwide biscuits, snacks and cereals business of Danone (‘Danone Biscuits’, France) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for Kraft: manufacture and sales of food and beverage products, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Kraft: manufacture and sales of food and beverage products,

| — | for Danone Biscuits: manufacture and sales of biscuits, snacks and cereals. |
| --- | --- |

—

for Danone Biscuits: manufacture and sales of biscuits, snacks and cereals.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4824 — Kraft/Danone Biscuits, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Bruxelles/Brussel |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4824 — Kraft/Danone Biscuits, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Bruxelles/Brussel

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

OTHER ACTS

Commission

| 28.9.2007 | EN | Official Journal of the European Union | C 228/18 |
| --- | --- | --- | --- |

28.9.2007

EN

Official Journal of the European Union

C 228/18

---

Publication of an application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs

(2007/C 228/07)

This publication confers the right to object to the application pursuant to Article 7 of Council Regulation (EC) No 510/2006. Statements of objection must reach the Commission within six months from the date of this publication.

SUMMARY

COUNCIL REGULATION (EC) No 510/2006

‘VŠESTARSKÁ CIBULE’

EC No: CZ/PDO/005/0437/23.11.2004

PDO ( X ) PGI ( )

This summary sets out the main elements of the product specification for information purposes.

1.   Responsible department in the Member State:

| Name: | Úřad průmyslového vlastnictví |
| --- | --- |
| Address: | Antonína Čermáka 2a |
| CZ-160 68 Praha 6 |

Name:

Úřad průmyslového vlastnictví

Address:

Antonína Čermáka 2a

CZ-160 68 Praha 6

Tel.

(420) 220 383 111

Fax

(420) 224 324 718

E-mail:

posta@upv.cz

2.   Group:

| Name: | Zemědělské družstvo Všestary |
| --- | --- |
| Address: | Rozběřice 18 |
| CZ-503 12 Všestary |

Name:

Zemědělské družstvo Všestary

Address:

Rozběřice 18

CZ-503 12 Všestary

Tel.

(420) 495 458 113

Fax

(420) 495 458 113

E-mail:

sekretariat@vsestary.cz

Composition:

Producers/processors ( X ) Other ( )

This application derogates from Article 5(1) of Council Regulation (EC) No 510/2006 on account of the fact that there is only one producer in the area — a cooperative, and therefore an association of owners. The requirements laid down in Article 2 of Commission Regulation (EC) No 1898/2006 are fulfilled.

3.   Type of product:

Class 1.6. — Onion

4.   Specification:

(Summary of requirements under Article 4(2) of Regulation (EC) No 510/2006)

4.1.   Name: ‘Všestarská cibule’

4.2.   Description: Shape: regularly spherical or ovate.

Appearance: the contents of each package are uniform; the surface comprises at least two layers of dry skin which cover the fleshy scales, forming a compact onion. The skin must not be moist or mouldy and the onion must not show signs of attack by diseases or pests.

Colour: the skin is golden yellow (it should not be dark brown), and the flesh is white to greenish white.

Taste: typical of onions, delicate, sweet; varying degree of hotness according to the variety.

Odour: sweet, typically pungent onion smell.

Varieties of ‘Všestarská cibule’ grown: Radar, Armstrong, Hyskin, Sedona, Hybelle, Sturon, Baldito, Narvito, Canto, Takmar, Takstar, Wellington, Viktory, Profit, Festival.

4.3.   Geographical area: Municipality of Všestary and the surrounding area, including the municipalities of Bříza, Rosnice, Světí, Rozběřice, Neděliště, Sendražice, Máslojedy, Čístěves, Horní Dohnalice, Střezetice and Probluz, in the Hradec Králové region of the Czech Republic.

4.4.   Proof of origin: The growing areas, stores and storage boxes, lots and wrapping dates are indicated. Records of purchasers are kept. Each delivery can therefore be unambiguously traced and deliveries are distinguishable from one another. The onions are graded, stored and wrapped within the defined area and cannot therefore be confused with onions grown elsewhere.

An inspector appointed by the producer checks compliance with the specification, focusing in particular on the quality of the seedlings, raw materials, growing methods (schedules, quantities of organic fertilisers, application of fertilisers) and storage conditions. The appearance, quality, wrapping, grading and sizing of the onion are checked daily. One of the main criteria is whether the onion is damaged, moist, mouldy or infected with neck rot. In the storage area, the air temperature and humidity levels are monitored in particular. The results are recorded in the inspection book, which is kept in the files. The following critical points are checked in particular: receipt of harvested onions and entry into storage, eco-roller system — check on the state of the onion and removal of impurities, storage and drying of the onion, transfer to the grading line, grading, sizing, wrapping and labelling, packaging, dispatch and transport. A check is carried out in particular for possible contamination with microorganisms, with chemical substances (mycotoxins, heavy metals) or with mechanical impurities (stones, earth), presence of pests or oil, unsuitable onions which should be removed, contaminated packaging and exposure to freezing temperatures. The grading, wrapping and distribution process has an HACCP certificate.

Weather conditions are attested by data from the Czech Hydrometeorological Institute. Analyses of the soil and of the onions are carried out by accredited external laboratories. Compliance with the specification, quality and compliance with laws, decrees and standards are also checked by the superior inspection body (Státní zemědělská a potravinářská inspekce, see point 4.7.), in accordance with the inspection plan of the competent inspectorate.

4.5.   Method of production: ‘Všestarská cibule’ is grown from high-quality hybrid seed and certified seedlings.

Method used to grow ‘Všestarská cibule’: the soil is prepared organically; it is thoroughly ploughed in the autumn; the soil is prepared in the autumn prior to planting; the winter onions are planted; the soil is prepared in the spring prior to sowing and planting; the seedlings are planted and the seeds sown; they are irrigated as required; weeding is carried out; nitrogenous fertilisers are applied; if necessary during the growing period, steps are taken to combat weeds, diseases and pests; the onions are topped and removed from the soil; they are collected after being allowed to dry; the onions are placed in the store; they are checked and impurities are removed on the eco-roller system; they are further dried and aired; they are graded and sized; the onions are wrapped in nets (3, 5, 10, 15, 20 or 25 kg) as required by the customer or presented in bulk in boxes of 10, 15, 20 or 25 kg, or possibly in other quantities by agreement; they are labelled and dispatched.

The modern storage facility, which is sufficiently dry and aired, enables onions to be stored for a period of 10 months while preserving their outstanding quality.

Storage and wrapping must be undertaken within the defined area. In this way, damage to the onion during transfer is avoided. This approach also guarantees that the onions are not mixed up with onions grown elsewhere. This coordinated process of growing, storing and wrapping in one place means that the onions do not deteriorate. They are distributed from the defined area as a finished product with the label ‘Všestarská cibule’.

4.6.   Link:

Characteristics, link

‘Všestarská cibule’ has four basic positive characteristics, which are linked to the environment and growing method. The unique nature of ‘Všestarská cibule’ derives from the:

| — | balance of their nutritional parameters, |
| --- | --- |

—

balance of their nutritional parameters,

| — | high level of iron, |
| --- | --- |

—

high level of iron,

| — | very high level of vitamin B3 (niacin), |
| --- | --- |

—

very high level of vitamin B3 (niacin),

| — | absence or low levels of harmful substances. |
| --- | --- |

—

absence or low levels of harmful substances.

Nutritional parameters — balance

Most of the nutritional parameters of ‘Všestarská cibule’ (formative substances, minerals, vitamins) are balanced, without extremes and correspond to the expected favourable characteristics of an onion. They comprise, for example, potassium, phosphorus and vitamins B1, B2 and B6.

Iron — high level

‘Všestarská cibule’ has a high iron content. According to the USDA — National Nutrient Database, the iron content of onion is 2,1 mg/kg, while ‘Všestarská cibule’ has 2,55 mg/kg, i.e. approximately 25 % more.

Vitamin B3 (niacin) — very high level

The level of vitamin B3 (niacin) contained in ‘Všestarská cibule’ is very high. According to the USDA — National Nutrient Database, the niacin content of onion is 0,116 mg/100 g, while ‘Všestarská cibule’ has 208 mg/100 g, i.e. approximately double.

Absence, or low or very low levels, of harmful substances

A significant feature of ‘Všestarská cibule’ lies in the absence, or low or very low levels, of harmful substances. For example, the level of Cd in ‘Všestarská cibule’ is below 0,03 mg/kg, compared with a standard of 0,05 mg/kg, and the level of NO3 in ‘Všestarská cibule’ is 29 mg/kg, compared with a standard of 1 000 mg/kg. ‘Všestarská cibule’ has been tested for dozens of possible harmful substances and complied with the levels in all cases.

Characteristics, link, environment, growing

The above-mentioned positive characteristics are linked to the environment and, in particular, to the following categories of factors:

| — | natural conditions, |
| --- | --- |

—

natural conditions,

| — | history of growing, |
| --- | --- |

—

history of growing,

| — | gentle growing method, |
| --- | --- |

—

gentle growing method,

| — | appropriate post-harvest processing. |
| --- | --- |

—

appropriate post-harvest processing.

Natural conditions

The natural conditions in the growing area comprise the landscape, the soil and the climate. The general natural conditions in the defined area are very good for growing onions.

Landscape: The altitude of Všestary is 265 metres above sea level and the growing plots are at an altitude of 245-320 meters. The region is therefore relatively low-lying, with plenty of sunshine. The relief of the landscape is slightly rugged and most of the plots are flat or gently sloping. The character of the landscape favours good moisture retention in the soil. It comprises a broad valley open to the South, in which there are rich layers of soil deposited from the River Elbe.

Soil: The local soils are made up of Quaternary sediments. The oldest rocks are from the Cretaceous formation, which occurs in the form of marl here. All the layers of the marl are, however, covered with deep loess deposits. Loess is the bedrock substratum virtually throughout the area. On these local loesses, as a result of a large number of soil-forming factors, the following genetic soil types have evolved in particular: slightly gleyed brown earth, and black earth. The soils in the defined area meet the best conditions for growing onions — they are warm, deep, moist, and rich in humus and nutrients, with a neutral pH reaction. The high natural humus content is also favourably influenced by the cropping pattern.

In view of their mineral content and pH, the soils are very suitable for growing onions. Dozens of samples of soils on nine plots were analysed and the mineral content (Ca, Mg, K, P) and pH were determined. All the results of the laboratory analyses demonstrated the suitability of the local soils for growing ‘Všestarská cibule’.

Climate: The area has equable climatic conditions.

Temperatures are mild and relatively constant, and the average monthly temperature is 6,9 °C, rising to 13,4 °C during the growing season of April to September.

The average monthly precipitation is 48 mm, with no extreme monthly variations; average monthly precipitation in the defined area is somewhat lower than in the Czech Republic as a whole. During the growing season, 437 mm of precipitation falls, the largest volume of which in the months of June (86 mm), July (83 mm) and August (84 mm).

The area's moderate prevailing winds from various directions contribute to the mild temperatures and help ensure suitable precipitation without extreme variations and aeration of the soil. At the same time, there are no extreme winds to cause excessive drying out of the countryside.

The overall mild climate with slight variations and lower levels of precipitation during the onion's growing season offers favourable climatic conditions for growing onions in the defined area. A fundamental merit of ‘Všestarská cibule’ lies in the fact that it is so little affected by variations in monthly or annual precipitation. The environmental conditions (landscape, climate and soil) help preserve adequate soil moisture even when the precipitation in a particular season or year is poor. Lack of precipitation does not affect the quality or the quantity of the onions produced. In the second half of the growing season the onions prefer a drier soil; in view of the natural conditions, therefore, producers need provide additional irrigation only rather exceptionally in the event of very dry weather.

History of growing

Onion-growing has a long tradition in the defined area. Large-scale onion-growing in Všestary was launched in 1964 by the managers of the then cooperative, taking account of the high fertility of the soil, favourable altitude and the construction of a new irrigation system along the river Elbe. Over the course of year of growing ‘Všestarská cibule’, the producer, its members and workers have identified which methods are most suitable for growing onions in the defined area and have been using those methods for a long time. In view of the high quality of the local onion, the growing tradition has continued until the present day, with good prospects for the future.

The producer is currently a cooperative with 112 members.

Gentle growing method

One of the prerequisites for obtaining the final properties of ‘Všestarská cibule’ also lies in the gentle growing method. The application of fertiliser is carried out on the basis of soil analyses. The soil does not therefore become exhausted and the ‘old soil strength’ is maintained. The mechanically gentle treatment of the soil is highly important. The Terragator has, for example, proved to be very suitable for applying fertiliser; this equipment, on the one hand, allows fertiliser to be dispensed precisely and, on the other, does not compact the soil (using a Terragator is not a prerequisite for growing ‘Všestarská cibule’, while fertilising contributes to the quality). This has a great influence on the permeability of the soil, uptake of nutrients and, therefore, the fertility of the soil. The soil is not damaged, no compaction occurs in the soil substrata, the rootlets of the plants can penetrate more deeply and the plant takes up nutrients even from the substrata. In this way, the soil is kept in excellent condition. In order to keep any environmental damage to a minimum, organic fertilisers are used as far as possible, particularly concentrated stillage and fertilisers prepared by composting with an active air flow, i.e. of the Bioganik type.

Appropriate post-harvest processing

The harvest is carried out during drier weather, so that the harvested onions can be dried directly in the field. The onions are collected by gentle means and carried a short distance to the producer's storage facility; they are wrapped direct from the storage facility and transported to the purchasers.

Through appropriate post-harvest processing (see 4.5), storage and wrapping ‘Všestarská cibule’ retains its natural parameters, which it has acquired from the natural environment in the field and through gentle growing methods. By minimising the distance and time required to transfer the harvested onions to the storage area and wrapping them practically straight from the store, the possibility of mechanical damage or rotting is reduced to a minimum.

The producer has a well-developed HACCP system, which largely eliminates damage to onions, contamination (impurities) and rotting during post-harvest processing. See also point 4.4 Proof of origin.

Awards

The Festival variety of the Všestary onion won an award in 2002 at the Fruit, Vegetables and Nursery-Stock Products Exhibition Hortikomplex Olomouc 2002, where it was placed first as best cultivar of the year.

The number of the entry in the Register of Designations of Origin of the Czech Republic is 181, the date of registration being 14 February 2002.

Link — conclusion

It was pointed out above that the characteristics of ‘Všestarská cibule’ derive from the growing area and from the growing and processing method. In particular, the soil analyses, in which the mineral results are mostly high or good and no results are low, have a direct link with the mineral and vitamin content of ‘Všestarská cibule’, with the good potassium and phosphorus content and especially with the fact that the iron and vitamin B3 content of ‘Všestarská cibule’ are high and very high respectively compared with ordinary onions.

4.7.   Inspection body:

| Name: | Státní zemědělská a potravinářská inspekce, Inspektorát v Hradci Králové |
| --- | --- |
| Address: | Březhradská 182 |
| CZ-503 32 Hradec Králové |

Name:

Státní zemědělská a potravinářská inspekce, Inspektorát v Hradci Králové

Address:

Březhradská 182

CZ-503 32 Hradec Králové

Tel.

(420) 495 454 110

Fax

(420) 495 532 518

E-mail:

hradec@szpi.gov.cz

4.8.   Labelling: —

---